文献速递眼底病与葡萄膜炎白内障与屈光手术

减少眼科成本-效用分析中潜在偏倚的机会

Opportunities to Reduce Potential Bias in Ophthalmic Cost-Utility Analysis.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

该经济学评价基于价值医疗中心数据库,比较白内障手术和新生血管性年龄相关性黄斑变性(NVAMD)雷珠单抗治疗中,使用非眼科患者视觉效用和/或系统共病效用上限模型对质量调整生命年(QALY)增益及成本-效用比的影响。结果显示这些方法大幅降低QALY增益和成本-效用,可能对残疾、老年和非洲裔美国人群产生潜在偏倚。

要点

  • 使用非眼科患者效用替代眼科患者效用会大幅降低白内障手术的QALY增益和成本-效用。
  • 将视觉效用增益限制在系统共病效用水平会进一步降低QALY增益和成本-效用。
  • 眼科医生应认识这些潜在偏倚,并考虑纠正对残疾、老年和非洲裔美国人群的歧视。

核心结论

  • 使用非眼科患者视觉效用和/或系统共病效用上限模型会大幅降低常见眼科干预的患者价值(QALY)增益和成本-效用。
  • 眼科医生应认识这些现象,并考虑纠正对残疾、老年和非洲裔美国人群的潜在歧视。

研究设计与样本

  • 该经济学评价主要使用价值医疗中心数据库,对白内障手术和NVAMD雷珠单抗治疗进行基于偏好的比较效果和成本-效用分析。
  • 使用眼科患者效用和非眼科患者(替代者)视觉效用,并整合或不整合系统共病效用限制。
  • 成本-效用分析采用3%贴现率,以2018年美元计。

主要发现

  • 非眼科患者队列共309人,眼科患者队列共505人。
  • 第一眼白内障手术参考案例(使用眼科患者效用且无系统共病效用限制)相比观察获得2.574(34.2%)的QALY增益。
  • 替换为非眼科患者效用后QALY增益为1.502(15.5%),使用0.76的患者系统共病效用限制白内障手术视觉效用增益后QALY增益为1.337(17.8%)。
  • 同时使用非眼科患者效用和系统共病效用限制后QALY增益为0.839(8.7%)。
  • NVAMD雷珠单抗治疗参考案例获得1.339(26.1%)的QALY增益;替换后QALY增益分别为1.164(22.7%)、1.001(19.5%)和0.971(18.9%)。

关键数值与推荐

  • 白内障手术成本-效用因非眼科患者效用下降71.3%(95%CI,70.6%-72.1%),因患者系统共病效用下降92.5%(95%CI,51.9%-133.1%),因两者同时使用下降206.8%(95%CI,202.6%-211.2%)。
  • NVAMD雷珠单抗治疗成本-效用因非眼科患者效用下降16.4%,因系统限制共病效用下降33.8%,因两者同时使用下降37.9%。

临床怎么用

  • 眼科医生应认识非眼科患者效用和系统共病效用上限模型可能引入的潜在偏倚。
  • 在成本-效用分析中考虑纠正对残疾、老年和非洲裔美国人群的潜在歧视。

局限性

  • 该研究主要基于价值医疗中心数据库,可能限制结果的普遍性。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Select research methods in cost-utility analysis (incremental cost-effectiveness analysis) might potentially bias against patient value (quality-adjusted life-year [QALY]) gain and cost-effectiveness associated with common ophthalmic interventions in disabled, elderly, and African American populations. OBJECTIVE: To ascertain whether using nonpatient vision utilities and/or a maximum limit model constraining vision utility gain to the systemic comorbidity utility level biases against ophthalmic cost-utility outcomes. DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation predominantly used data from the Center for Value-Based Medicine database to perform preference-based comparative effectiveness and cost-utility analyses for cataract surgery and intravitreal ranibizumab therapy for neovascular age-related macular degeneration (NVAMD) using vision utilities acquired from patients with ophthalmic disease (ophthalmic patient utilities) and from surrogate individuals (nonophthalmic patient vision utilities) with and without integrating systemic comorbidity utility limits on vision utility gain. Ophthalmic patient data were collected from January 1, 2000, to December 31, 2016, and analyzed from April 1 to July 1, 2020. INTERVENTIONS: Cost-utility analysis with 3% discount rate in 2018 US dollars. MAIN OUTCOMES AND MEASURES: QALY gains and dollars expended per QALY gain (the cost-utility ratio). RESULTS: A total of 309 participants in the nonophthalmic patient cohort and 505 patients in the ophthalmic patient cohort were included. A reference case of first-eye cataract surgery using ophthalmic patient vision utilities and no systemic comorbidity utility limits yielded a 2.574 (34.2%) QALY gain vs observation. Substituting nonophthalmic patient utilities resulted in a 1.502 (15.5%) QALY gain, whereas using the 0.76 patient systemic comorbidity utility to limit cataract surgery vision utility gain yielded a 1.337 (17.8%) QALY gain. Using both nonophthalmic patient utilities and systemic comorbidity utility limits yielded a 0.839 (8.7%) QALY gain. The substitutions decreased cataract surgery cost-effectiveness by 71.3% (95% CI, 70.6%-72.1%) for nonophthalmic patient utilities, 92.5% (95% CI, 51.9%-133.1%) for patient systemic comorbidity utility, and 206.8% (95% CI, 202.6%-211.2%) for both. The NVAMD ranibizumab therapy reference case yielded a 1.339 (26.1%) QALY gain. Similar substitutions resulted in QALY gains of 1.164 (22.7%) for nonophthalmic patient utilities while reducing cost-effectiveness by 16.4%, 1.001 (19.5%) for systematic-limiting comorbidity utility while reducing cost-effectiveness by 33.8%, and 0.971 (18.9%) for both while reducing cost-effectiveness by 37.9%. CONCLUSIONS AND RELEVANCE: Using nonophthalmic patient vision utilities and/or the maximum limit model of limiting patient utility gains to the population systemic comorbidity utility level resulted in large decreases in patient value (QALY) gain and cost-effectiveness for common ophthalmic interventions. Ophthalmologists should realize these phenomena and consider correcting the potential discrimination against disabled, elderly, and African American populations. This negative potential bias could theoretically result in beneficial intervention denial, less research dollars, curbed therapeutic advances, and decreased interventional reimbursement.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Brown GC, Brown MM, Chaudhry I, et al. Opportunities to Reduce Potential Bias in Ophthalmic Cost-Utility Analysis. JAMA Ophthalmol. 2021. PMID: 33538789. doi:10.1001/jamaophthalmol.2020.6591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。